Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 telitacicept versus placebo in active primary Sjögren’s disease
NL-OMON61718Phase 3Not yet recruiting
- Sponsor
- Vor Bio
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Sjögren's syndrome comparing Telitacicept 160 mg with Placebo (2 arms). Primary endpoint: Change from baseline in EULAR Sjögren’s Syndrome Disease Activity Index. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON61718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61718.